Reversion of the hematological and hematopoietic alterations produced by 4T1 murine breast tumor through docetaxel

MAURO, F; MERCOGLIANO MF; BRUNI S; SCHILLACI R; ELIZALDE PV

Congreso; Reunión Anual de SAIC; 2020

Docetaxel (D) is a chemotherapeutic agent widely used in several types of malignancies including breast cancer. Here we studied the impact of D on hematopoietic populations in the bone marrow (BM) and the hematological parameters in peripheral blood in both healthy and 4T1 tumor bearing mice, as a model of triple negative breast cancer. We also studied the impact of D on the proliferation, migration and survival of 4T1 cells in vitro. 4T1 cells were injected subcutaneously in female BALB/c mice and, when tumors established, they were treated with D 10 mg/kg twice a week for 3 weeks or vehicle. Healthy mice were injected with vehicle (control) or D. After treatment, we determined the hemogram and identified hematopoietic precursors by immunofluorescence and flow cytometry. Proliferation and survival assays were performed by Trypan Blue count, and migration by wound healing assay. Mice with 4T1 tumor developed a myeloid leukemoid reaction with a high granulocytic count (p